First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and AdrulipaseBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced

Related Keywords

Boca Raton ,Florida ,United States ,James Sapirstein ,David Schemelia ,World Health Organization ,Company Annual Report On Form ,First Wave Biopharma Inc ,Nasdaq ,Tiberend Strategic Advisors Inc ,Drug Administration ,First Wave Bio Inc ,Exchange Commission ,First Wave Biopharma ,Wave Biopharma ,Proposed Transaction ,First Wave ,First Wave Bio ,Annual Report ,Strategic Advisors ,Ulcerative Colitis ,Iopharmaceutical Company ,Inflammatory Bowel Diseases ,Exocrine Pancreatic Insufficiency ,Niclosamide ,Development Pipeline ,Iopharma ,